Oxford 12 April 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today that research on CXD101 its novel dual action HDAC inhibitor had been presented at the Inaugural Meeting of the Oxford Centre for Cancer Gene Research, run concomitantly with the 3rd meeting of the Colorectal Cancer Networking Group.
The meeting was held in Oxford UK and focused on the role of genes and the management of genetic changes in the treatment of colorectal cancer. Through its novel mode of action CXD101 has a key role in reinstating epigenetic control in cancer. CXD101 has been shown to have potential in Colorectal Cancer (CRC) both alone and particularly in combination with checkpoint inhibitors, in addition to potential in other
solid tumours and in haematological malignancies.
Two presentations of CXD101 were made at the meeting; Prof Nick La Thangue, CEO of Celleron Therapeutics, reviewed the fundamental research in epigenetics, which has led to the development of CXD101 and recent results showing its unique immune-modulatory effects on tumour cells. Professor David Kerr, CMO of Celleron Therapeutics, then presented the clinical data from the Phase 1 programme with CXD101 showing both clinical efficacy as monotherapy and that the product is very well tolerated as oral therapy, before going on to discuss the future potential of CXD101 in CRC. Phase 2 trials are planned to start in 2017.
Celleron secured Series B investment from leading South Korean financial institutions including Korea Investment Partners, NHN Investment, IMM Investment and KTB Network. Theragen Etex, a listed Korean biopharmaceutical company, also participated in the financing round. The financing round represents the first time that a UK biopharmaceutical company has been financed by South Korean investors.
Professor David Kerr said:
“We were very pleased to present CXD101 at this important meeting and to have the opportunity to discuss the novel research and the exciting clinical plans which could lead to significant benefit for patients with colorectal cancer”
About Celleron Therapeutics
Celleron Therapeutics, based on the Oxford Science Park, UK, is a drug development company focussed on precision medicine for cancer. It is a spin-out of Oxford University and has secured a number of exclusive licence agreements with pharmaceutical companies, including Astra Zeneca. Celleron’s precision medicine approach is supported by a companion diagnostic biomarker platform, which allows new drugs to be tailored to responsive tumours. Celleron has two Phase 2 clinical assets: CXD101 is a novel dual mechanism HDAC inhibitor which has unique immuno-modulatory effects in tumour cells, and CXD201 represents a new type of topoisomerase inhibitor.
Celleron Therapeutics Ltd.
Oxford Science Park